Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases

Thyroid

Volumn 24, Issue 7, 2014, Pages 1088-1095

  Sabra, Mona M ^a   Grewal, Ravinder K ^a   Ghossein, Ronald A ^a   Tuttle, R Michael ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ADJUVANT THERAPY; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CERVICAL LYMPH NODE; COMPARATIVE STUDY; DRUG MEGADOSE; DRUG UPTAKE; FEMALE; HUMAN; LOW DRUG DOSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT RESPONSE; TUMOR ABLATION; ADOLESCENT; AGE; AGED; CARCINOMA, PAPILLARY; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SECONDARY; THYROID NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECK DISSECTION; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904012914     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0465     Document Type: Article

References (18)

1. Podnos YD, Smith D, Wagman LD, Ellenhorn JD 2005 The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 71:731-734
2. Zaydfudim V, Feurer ID, Griffin MR, Phay JE 2008 The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery 144:1070-1077
3. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, Travagli JP, Schlumberger M 2005 Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90:5723-5729
4. Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, Tufano RP, Tuttle RM 2012 American Thyroid Association Surgical Affairs Committee's Taskforce on Thyroid Cancer Nodal Surgery. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22:1144-1152
5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
6. Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw 2010 8:1277-1286
7. Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA 2002 Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 87:5817-5820
8. Mandel SJ, Mandel L 2003 Radioactive iodine and the salivary glands. Thyroid 13:265-271
9. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) 2004 World Health Organization Classification of Tumours. Pathology and Genetics Tumours of the Endocrine Organs. Lyon: IARC Press
10. Ghossein R, Livolsi VA 2008 Papillary thyroid carcinoma tall cell variant. Thyroid 18:1179-1181
11. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) 2009 AJCC Cancer Staging Manual. Seventh edition. New York: Springer-Verlag
12. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in Differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the New American Thyroid Association staging system. Thyroid 20:1341-1349
13. Robbins RJ, Srivastava S, Shaha A, Ghossein R, Larson SM, Fleisher M, Tuttle RM 2004 Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab 89:6010-6016
14. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-Term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899
15. Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S 1984 An analysis of ''ablation of thyroid remnants'' with I-131 in 511 patients from 1947-1984: Experience at University of Michigan. J Nucl Med 25: 1287-1293
16. Verburg FA, Lassmann M, Mäder U, Luster M, Reiners C, Hänscheid H. The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients 2011 Eur J Nucl Med Mol Imaging 38:673-680
17. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, Chan CY 2006 Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 47:1587-1591
18. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA 2013 Selumetinibenhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 14:623-632